Page 1

EX - 99.1 2 brhc10030173_ex99-1.htm EXHIBIT 99.1 insmed Exhibit 99.1 Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update —ARIKAYCE® ( amikacin liposome inhalation suspension ) Now Launched in Three Major Territories ; Positive Early Trends in Japan- -Continuing to Advance ARIKAYCE , Brensocatib , and Treprostinil Palmitil Inhalation Powder ( TPIP ) Clinical Development Programs― —ARIKAYCE Total Revenue of $ 46.8 Million for the Third Quarter 2021— -Strong Cash Position of $ 846.6 Million as of September 30 , 2021- BRIDGEWATER , N.J. , October 28 , 2021 / PRNewswire / - Insmed Incorporated ( Nasdaq : INSM ) , a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases , today reported financial results for the third quarter ended September 30 , 2021 and provided a business update . " In the third quarter of 2021 , Insmed made important progress against our strategic priorities , including steady performance of our commercial operations , advancement of our clinical development programs in line with expectations , and meaningful acceleration of our translational medicine efforts with a sharp focus on disruptive technologies that we believe will have a significant impact on patients ' lives , " commented Will Lewis , Chair and Chief Executive Officer of Insmed . “ Notably , we are excited about our launch progress for ARIKAYCE in Japan , where we are already seeing positive early trends . As we navigate this critical execution period for Insmed , we are well - capitalized and highly driven to launch the next phase of growth for our company and to serve many more patients around the world . " Recent Corporate Developments & Program Highlights ARIKAYCE • • Insmed launched ARIKAYCE in Japan in July of 2021 , with a price in line with list prices in the U.S. and Europe . Initial uptake in Japan has been strong , with several positive trends at this early stage of the launch . Insmed continues to advance the launch of ARIKAYCE in Europe . In addition to previous launches in Germany and the Netherlands , ARIKAYCE has been reimbursed and launched in Wales as of September of 2021. The Company is pursuing country - by - country reimbursement throughout Europe , with a near - term focus on Ireland , additional UK countries , Italy , Belgium , and France . Enrollment continues in line with expectations in the post - approval confirmatory frontline clinical trial program of ARIKAYCE in patients nontuberculous mycobacterial ( NTM ) lung disease caused by Mycobacterium avium complex ( MAC ) . The program consists of ARISE , an interventional study designed to validate a patient - reported outcome ( PRO ) tool in MAC lung disease , and ENCORE , a pivotal trial designed to establish , using the PRO tool validated in the ARISE trial , the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed MAC lung disease . Insmed presented data this quarter at ID Week 2021 and the CHEST Annual Meeting that advance the understanding of NTM lung disease and underscore the importance of appropriate diagnosis and management . 1